Contrafect Corporation
Records under this name other than the patents Contrafect Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Contrafect Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,524,046 | Biofilm Prevention, Disruption and Treatment with Bacteriophage Lysin Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,639,370 | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,246,928 | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,144,845 | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,491,245 | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,773,140 | Gram-Negative Lysin-Antimicrobial Peptide (AMP) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof in Human Serum Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,121,568 | Identification of Lysins and Derivatives Thereof with Bactericidal Activity Against Pseudomonas Aeruginosa Formerly held In force · High confidence | In force | High confidence | |
| US 11,413,334 | Lysin Polypeptides Active Against Gram-Negative Bacteria Formerly held Lapsed on the fee record Ended Aug 16, 2026 · High confidence | Lapsed on the fee record | Ended Aug 16, 2026 | High confidence |
| US 11,357,833 | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby Lapsed on the fee record Ended Jun 14, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2026 | USPTO record |
| US 9,889,181 | Bacteriophage Lysin and Antibiotic Combinations Against Gram Positive Bacteria Formerly held Lapsed on the fee record Ended Feb 13, 2026 · Low confidence | Lapsed on the fee record | Ended Feb 13, 2026 | Low confidence |